World's Best Scientists 2026 revealed!
Thomas E. Witzig

Thomas E. Witzig

D-Index & Metrics

Medicine

D-Index
148
Citations
81366
World Ranking
1237
National Ranking
718

Overview

Thomas E. Witzig is affiliated with the Mayo Clinic in the United States. Their research primarily focuses on medical fields related to lymphoma and hematologic malignancies, producing significant work in areas such as pathology, oncology, and genetics.

Their main fields of study include:

  • Medicine

Within medicine, their subfields of study cover:

  • Pathology and Forensic Medicine
  • Oncology
  • Genetics
  • Molecular Biology
  • Neurology

The research topics addressed by Thomas E. Witzig encompass a range of hematologic cancers and therapies, including:

  • Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Viral-associated Cancers and Disorders
  • CAR-T Cell Therapy Research
  • CNS Lymphoma Diagnosis and Treatment
  • Acute Lymphoblastic Leukemia Research
  • Acute Myeloid Leukemia Research

The most frequent publication venues for Witzig's work are:

  • Blood
  • Journal of Clinical Oncology
  • Clinical Lymphoma Myeloma & Leukemia
  • Blood Cancer Journal
  • Hematological Oncology

Notable recent papers include:

  • ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma (2021), Journal of Clinical Oncology
  • Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412 (2021), Journal of Clinical Oncology
  • RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis (2021), Nature Communications
  • A Review of Pathophysiology, Clinical Features, and Management Options of COVID-19 Associated Coagulopathy (2020), Shock
  • Lack of intrafollicular memory CD4+ T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma (2021), Blood Cancer Journal

Thomas E. Witzig has frequently collaborated with the following co-authors:

  • Thomas M. Habermann
  • Grzegorz S. Nowakowski
  • Stephen M. Ansell
  • James R. Cerhan
  • Matthew J. Maurer

Best Publications

  • Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

    Sattva S. Neelapu;Frederick L. Locke;Nancy L. Bartlett;Lazaros J. Lekakis

  • Review of 1027 Patients With Newly Diagnosed Multiple Myeloma

    Robert A. Kyle;Morie A. Gertz;Thomas E. Witzig;John A. Lust

  • Effective surgical adjuvant therapy for high-risk rectal carcinoma.

    J E Krook;C G Moertel;L L Gunderson;H S Wieand

  • Targeting apoptosis pathways in cancer therapy.

    Irene M. Ghobrial;Thomas E. Witzig;Alex A. Adjei

  • Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

    Thomas E. Witzig;Leo I. Gordon;Fernando Cabanillas;Myron S. Czuczman

  • International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease

    A. Khosroshahi;Z. S. Wallace;J. L. Crowe;T. Akamizu

  • Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis

    Angela Dispenzieri;Morie A. Gertz;Robert A. Kyle;Martha Q. Lacy

  • POEMS syndrome: definitions and long-term outcome.

    Angela Dispenzieri;Robert A. Kyle;Martha Q. Lacy;S. Vincent Rajkumar

  • Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma

    Thomas E. Witzig;Ian W. Flinn;Leo I. Gordon;Christos Emmanouilides

  • A Trial of Three Regimens for Primary Amyloidosis: Colchicine Alone, Melphalan and Prednisone, and Melphalan, Prednisone, and Colchicine

    Robert A. Kyle;Morie A. Gertz;Philip R. Greipp;Thomas E. Witzig

  • Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.

    S. Vincent Rajkumar;Suzanne R. Hayman;Martha Q. Lacy;Angela Dispenzieri

  • Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+ B-Cell Non-Hodgkin's Lymphoma

    Thomas E. Witzig;Christine A. White;Gregory A. Wiseman;Leo I. Gordon

  • Rituximab for IgG4-related disease: a prospective, open-label trial

    Mollie N Carruthers;Mark D Topazian;Arezou Khosroshahi;Thomas E Witzig

  • Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma

    S. Vincent Rajkumar;Suzanne Hayman;Morie A. Gertz;Angela Dispenzieri

  • Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines

    Shaji K. Kumar;Joseph R. Mikhael;Francis K. Buadi;David Dingli

  • Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma

    Thomas E. Witzig;Susan M. Geyer;Irene Ghobrial;David J. Inwards

  • Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.

    Yazan Alsayed;Hai Ngo;Judith Runnels;Xavier Leleu

  • Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma

    Zhi Zhang Yang;Anne J. Novak;Mary J. Stenson;Thomas E. Witzig

  • Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience

    Phil A Hart;Mark D Topazian;Thomas E Witzig;Jonathan E Clain

  • Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Commentary

    Michele Cavo;S. Vincent Rajkumar;Suzanne R. Hayman;Martha Q. Lacy

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are interested in the medical field but seeking alternative or flexible study options, there are a variety of online degrees and related career pathways worth considering. For those with a non-nursing background aiming for advanced roles, msn direct entry programs online allow you to earn a master's degree in nursing without a traditional BSN, helping you fast-track your career.

Entry requirements and competitiveness can vary widely in healthcare education. Some might be searching for the easiest nursing programs to get into, which can be a great option for those looking for accessible admission pathways.

Not all healthcare careers require clinical work. Many learners explore online medical billing and coding with financial aid, an area growing in demand with options for financial assistance.

Additionally, if standardized testing is a challenge, you might consider enrolling in a nursing school that doesn't require teas or HESI exams, which can simplify the admissions process.

Best Scientists Citing Thomas E. Witzig

Trending Scientists